The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of S-1 in combination with sorafenib in metastatic renal cell carcinoma.
Hideki Sakai
No relevant relationships to disclose
Kojiro Ohba
No relevant relationships to disclose
Katsuyoshi Hashine
No relevant relationships to disclose
Yoshihiko Tomita
No relevant relationships to disclose
Nobuo Shinohara
No relevant relationships to disclose
Masato Fujisawa
No relevant relationships to disclose
Masatoshi Eto
No relevant relationships to disclose
Seiichiro Ozono
No relevant relationships to disclose
Taiji Tsukamoto
Consultant or Advisory Role - Taiho Pharmaceutical Co., Ltd.
Hideyuki Akaza
Consultant or Advisory Role - Taiho Pharmaceutical
Seiji Naito
Consultant or Advisory Role - Ono Pharmaceutical ; Pfizer